Why the study?
Does candesartan reduce the risk of new-onset type 2 diabetes and cardiovascular disease compared to enalapril in hypertensive patients?
Does candesartan reduce the risk of new-onset type 2 diabetes and cardiovascular disease compared to enalapril in hypertensive patients?
In hypertensive patients, initiation of candesartan was associated with a lower risk of new-onset type 2 diabetes and lower discontinuation rates compared to enalapril, with no difference in cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Should not yet change antihypertensive selection; hypothesis-generating for ARB diabetes benefit versus ACEIs, needing RCTs.
Hasvold et al. (2014) studied this question.